Liquidia Corporation

Liquidia Corporation

LQDA·NASDAQ

$55.69

+1.5%
HealthcareBiotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

At a Glance

Live Snapshot
Market Cap$4.95B
EPS-0.8000
P/E Ratio-69.61
Earnings Date08/11/2026

lqda

Total Non-Current Assets

Last Annual Value

137.25M

3-Year CAGR

67%

5-Year CAGR

33%

10-Year CAGR

38%

Liquidia Corporation

Liquidia Corporation Competitors Analysis of Total Non-Current Assets

LQDA · NASDAQ
CompanyTotal Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
137.25M
69.0%33.4%38.4% 
27.25M
-13.9%23.6%16.7%
13.62M
17.4%48.2%N/A
244.20M
39.6%-13.6%10.6%
ETNB logo
89bio, Inc.
NASDAQ:ETNB
2.23M
-6.5%38.4%N/A
187.02M
-3.8%6.8%5.2%
132.00M
-20.6%-16.8%29.4%
25.93M
9.4%13.8%17.8%
355.17M
50.9%-1.0%19.6%
Liquidia Corporation

Liquidia Corporation Fair Value Envelope

LQDA · NASDAQ

Our analysis suggests that LQDA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $55.69, this represents a potential HIDDEN relative to our calculated worth for Liquidia Corporation.

Intrinsic Value
Current Price: $55.69